CJC-1295-NO-DAC | Reference Standard

Short-Acting GHRH Analog for Pulsatile Endocrine Signaling Research

Category:
Endocrine & Hormonal Signaling • Growth Hormone Axis Research

What Researchers Study

CJC-1295 (No DAC) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) designed to stimulate endogenous growth hormone (GH) release through activation of GHRH receptors in the anterior pituitary.

Unlike the DAC-modified variant, CJC-1295 (No DAC) lacks albumin-binding functionality, making it a useful research tool for studying short-acting, pulsatile GH signaling that more closely resembles native GHRH dynamics in experimental models.

Primary Signal Pathways Studied

Research involving CJC-1295 (No DAC) focuses on:

• GHRH receptor activation on pituitary somatotroph cells

• Endogenous GH secretion patterns, particularly pulsatility and amplitude

• Downstream IGF-1 signaling, secondary to GH release

• Comparative GHRH analog behavior, versus long-acting or DAC-modified peptides

Because it clears more rapidly than DAC-modified analogs, CJC-1295 (No DAC) is often used to examine acute endocrine responses rather than sustained hormonal elevation.

Why This Peptide Is Studied

Native GHRH has an extremely short biological lifespan, limiting its experimental utility. CJC-1295 (No DAC) was developed to modestly improve stability while still allowing researchers to:

• Study physiological-style GH pulses

• Compare short-acting vs long-acting GHRH analogs

• Examine pituitary responsiveness without prolonged receptor engagement

• Model endocrine feedback mechanisms more precisely

This makes CJC-1295 (No DAC) especially useful in endocrine physiology, hormone-axis modeling, and comparative signaling research.

Research Areas of Interest

Endocrine Physiology Research

CJC-1295 (No DAC) is widely studied in pituitary and hypothalamic models to assess GH release kinetics and receptor sensitivity.

GH / IGF-1 Axis Modeling

Researchers use this peptide to explore downstream IGF-1 signaling while maintaining tighter experimental control over GH exposure duration.

Comparative Peptide Pharmacology

CJC-1295 (No DAC) is frequently studied alongside DAC-modified variants to understand how peptide modifications alter endocrine signaling behavior.

Selected Scientific References

• Teichman et al., Journal of Clinical Endocrinology & Metabolism — GHRH analog–mediated GH release dynamics

• American Journal of Physiology — Pituitary GHRH receptor signaling mechanisms

• Endocrine Reviews — Regulation of the GH/IGF-1 axis

(References provided for educational context and literature navigation.)

Product Specifications

• Compound Name: CJC-1295 (GHRH analog, no Drug Affinity Complex)

• CAS Number: 446036-97-1

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂ (reported values vary by source and salt form)

• Amino Acid Sequence:
  Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

• Molecular Weight: 3,367.2 Da

• Purity: ≥98% (HPLC verified)

• Form: Lyophilized powder

• Appearance: White to off-white solid

• Storage: ≤ –20 °C, desiccated, protected from light

Batch Documentation & Traceability

Each vial is shipped with a lot-specific QR code that provides secure access to batch documentation, including:

• Certificate of Analysis (COA)
• Identity verification report (HPLC / MS)
• Lot number, potency, and expiration

Documentation is locked to the specific batch shipped to ensure traceability, version control, and research reproducibility.

QR access is provided with the physical product and is not reused across lots.

Research Use Disclaimer

This product is supplied strictly for laboratory research and in-vitro or preclinical investigation.
Not for human or veterinary use.
Not for diagnostic, therapeutic, or consumptive applications.